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Background: Health Technology Reassessment (HTR) is a structured, evidence-based assessment of the clinical,
social, ethical and economic effects of a technology currently used in the health care system, to inform optimal use
of that technology in comparison to its alternatives. Little is known about current international HTR practices. The
objective of this research was to summarize experience-based information gathered from international experts on
the development, initiation and implementation of a HTR program.
Methods: A mixed methods approach, using a survey and in-depth interviews, was adopted. The survey covered 8
concepts: prioritization/identification of potentially obsolete technologies; program development; implementation;
mitigation; program championing; stakeholder engagement; monitoring; and reinvestment. Members of Health
Technology Assessment International (HTAi) and the International Network of Agencies for Health Technology
Assessment (INAHTA) formed the sampling frame. Participation was solicited via email and the survey was
administered online using SurveyMonkey. Survey results were analyzed using descriptive statistics. To gather more
in-depth knowledge, semi-structured interviews were conducted among organizations with active HTR programs.
Interview questions were developed using the same 8 concepts. The hour-long interviews were recorded,
transcribed and analyzed using constant comparative analysis.
Results: Ninety-five individuals responded to the survey: 49 were not discussing HTR, 21 were beginning to discuss
HTR, nine were imminently developing a program, and 16 participants had programs and were completing
reassessments. The survey results revealed that methods vary widely and that although HTR is a powerful tool, it is
currently not being used to its full potential. Of the 16 with active programs, nine agreed to participate in follow-up
interviews. Interview participants identified early and extensive stakeholder engagement as the most important
factors for success. A lack of top-down support and financial and human resources are inhibiting program
development.
Discussion: HTR is in its infancy. Although HTRs are being conducted, there are no standardized approaches.
However, much can be learned from current international work. Future work should focus on developing a
comprehensive methodology, reporting the processes of reassessments and sharing successes and challenges in a
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Health Technology Reassessment (HTR) has been gar-
nering interest over the past decade as a method of im-
proving quality of care and financial sustainability. HTR
is a structured, evidence-based assessment of the cli-
nical, economic, ethical, and social effects of a techno-
logy currently being used in the health care system, to
inform optimal use of that technology in comparison to
its alternatives [1]. There are a number of potential out-
comes from HTR including the removal of funding from
an ineffective technology, narrowing or broadening the
scope of a technology’s use or sustaining existing fund-
ing [2]. As such, HTR is a tool that can improve public
health, promote evidence-based decision-making and
ensure optimal allocation of financial resources [3]. One
of the goals of HTR is to identify areas of waste in a
health care system by reassessing clinical value [2]. HTR
is closely tied to Health Technology Assessment (HTA),
yet takes place once the technology is already being used
in clinical settings [4]. Technologies that are reassessed
may have previously gone through the HTA process be-
fore they were introduced or may have never been
assessed [2].
A recent systematic review revealed that there is only
one published model for HTR [5]. The systematic review
also found that a number of countries are actively com-
pleting health technology reassessments. However, there
is little literature available on the practicality of success-
fully establishing a HTR program. The purpose of this
study is to summarize experience-based information
gathered through a survey and key informant interviews
on the development, initiation, implementation and
monitoring of a HTR program.
Methods
Data collection
A mixed methods approach, using a survey and in-depth
interviews, was used to gather experiential knowledge.
This approach was used in order to acquire an overview
of the state of HTR activity internationally while gaining
a deeper understanding of the mechanics and practical-
ities of established HTR programs.
A convenience sampling strategy was used. The sam-
pling frame consisted of the organizational and indi-
vidual members of Health Technology Assessment
International (HTAi) and the organizational members
of the International Network of Agencies for Health
Technology Assessment (INAHTA); the two major
international organizations of health technology assess-
ment producers and users. A pre-notification email
was sent to this sample seeking participation and
requesting the name of a contact within their
organization knowledgeable in HTR. Six days subse-
quently, an email containing the survey link was sentout. This link went out to the contacts who were
identified as being involved in HTR and to the indivi-
duals who did not respond to the pre-notification
email. The survey questions were developed to obtain
information on eight broad areas that were defined a
priori from a systematic review of the literature, as
important facets of the HTR process: identification
and prioritization of potentially obsolete technologies;
program development; implementation; mitigation;
program championing; stakeholder engagement; monito-
ring; and reinvestment. An online tool, SurveyMonkey,
was used to conduct the survey from October 24th –
November 7th, 2011.
The online survey was designed to stream partici-
pants into one of three sets of questions based on the
organization’s stage of program development (Additional
file 1: Appendix I). Respondents who indicated they
had an active HTR program were also asked to partici-
pate in a voluntary follow-up interview. These inter-
views were conducted between November 22nd and
December 14th, 2011. Interviews ranged in length
from 30 to 90 minutes. A semi-structured interview
guide was developed to guide these interviews. This
guide evolved over the course of the interviews, as
questions were refined to reflect what had been
learned through the previous interview(s). Interviews
were audio-taped and transcribed with the partici-
pants’ consent. Where no consent was given detailed
notes were taken during the interview. Backup notes
were taken for all interviews.
Analysis
Basic descriptive statistics were used to summarize the
survey findings. Frequencies and proportions were used
to report the categorical variables. SurveyMonkey was
used for all quantitative analysis.
Using constant comparative analysis, transcripts and
notes were reviewed with the purpose of identifying key
themes relative to the interview questions. Data manage-
ment and analysis was facilitated through the use of
mind-mapping software that supported the identification




The survey was sent to a total of 2,123 individuals;
ninety-five responded (Figure 1). Of these, 49 (51.6%)
did not have a HTR program and were not planning to
develop one. Twenty-one (22.1%) noted that they were
aware of and beginning to discuss the development of a
HTR program. Nine (9.4%) responded that within the
near future they would be developing a program; poten-
tial start-up dates for these programs ranged from
Survey Participants 
n= 95 
We have an active health technology 
reassessment program 
n= 16 
Not currently discussing a health technology 




Aware of and beginning to discuss the 







We intend to begin a health technology 
reassessment program in the immediate future 
n= 9
Contacted for interview 
n= 11 
Figure 1 Flow chart of participant inclusion and exclusion.
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they had an established program and were currently
reassessing health technologies.
Many countries were represented in the survey in-
cluding Spain, Scotland, England, Norway, Australia,
US, Argentina, Italy, France, Russia, Sweden, Thailand,
Brazil, and Mexico. The majority (59.1%) of the survey
respondents identified themselves as either researchers
or senior managers. Nearly 34% responded that their
role fit into an ‘other’ category, which included econo-
mists, professors, students, pharmacists and research
fellows.
Nineteen of the 49 respondents who were not consid-
ering developing a HTR program cited that reassessment
was not within their mandate. Seventeen of these
nineteen respondents said that they had insufficient
resources to develop the program, such as inadequate
funding, time and qualified personnel, as the reason
for not developing a HTR program.
Those with established or developing programs were
asked why their organization decided to invest in the de-
velopment of a HTR program (Figure 2). When the data
from the active and developing programs were combined
(n = 25), government interest was the most frequently
cited reason for establishing a HTR program. Publicinterest was the least common reason for developing a
program. Participants were additionally asked to identify
the objectives of their program (Figure 3). Informing
health policy was the most frequently cited objective
(n = 15), followed by the creation of evidence-based
guidance (n = 14) and improving health care delivery
(n = 14).
In the survey, participants identified barriers they
had encountered during development and implementa-
tion. Those still in the development stage responded
that the top three barriers were: a lack of expertise in
HTR (n = 10); political barriers (n = 9); and a lack of
interest (n = 9). Those who have an active program cited
political barriers (n = 10) as the most significant hurdle
followed by a lack of expertise in the field (n = 6).
Nine of the sixteen individuals with active programs
noted that their organization is responsible for mitiga-
ting barriers that arise during the HTR implementation
process. Survey results suggest that most organizations
use championing and stakeholder engagement as pri-
mary means of barrier mitigation. Common types of
stakeholder engagement include: involving clinicians to
increase buy-in; and having public representatives
involved in the process to increase knowledge of the
HTR process.
Figure 2 Survey question results from participants with established or developing programs.
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logy reassessments, 11 have a champion for the program
(Figure 4). Of these eleven, nearly half responded that
this champion was affiliated with government. Sixty per-
cent (n = 14) of the individuals beginning to develop a
program responded that they have a champion. In this
case, the affiliation was evenly distributed between go-
vernment, academia, and health care administration.
Participants with established or developing programs
(n = 25) were asked how recommendations or decisions
to reduce or remove funding for a technology would be
implemented. Fifty-four percent of the organizations
developing a program responded that they only have ad-
visory capabilities; and therefore, the final reassessmentFigure 3 Survey question results from participants with
established or developing programs.decisions lie in the hands of an external decision-maker.
Less than five percent responded that their organization
had the ability to directly implement a HTR decision.
Fifty percent of those who were part of an established
HTR program said that they had advisory capabilities,
whereas over 20% noted that they controlled funding
decisions and therefore could implement their HTR
decisions.
Participants who had established or developing pro-
grams, were also asked “If funds are removed from a
technology that is reassessed, what happens to the
resources that were allocated to it?” Four of the respon-
dents with an established program noted that after dis-
investment, funds are reallocated to a more efficacious
technology; of those with a program in the development
stage, eight noted that the funds were reallocated to a
more efficacious technology. The survey results also
revealed that many individuals involved in reassessment
do not know what happens to funds that are liberated.
Six organizations with developing programs and three
with established programs were unsure of what would
happen with liberated funds.Key informant interviews results
The sixteen survey respondents who indicated that their
organization had an active reassessment program were
invited to participate in a follow-up interview; nine indi-
cated interest. These nine interview participants came
from six jurisdictions: Australia, UK, Canada, Sweden,
Costa Rica, and Italy; and consisted of policy decision-
makers, researchers, senior managers, and government
officials. As described previously, the purpose of these
interviews was to obtain in-depth perspectives on the
key questions asked in the survey.
Figure 4 Survey question results from organizations actively completing reassessment projects.
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participants affiliated with academic settings generally
noted that their HTR program was established with the
goal of developing robust HTR models with rigorous
economic evaluation components. Those affiliated with
government tended to see HTR as a promising approach
to improve fiscal sustainability in health care. At the
health care delivery level, HTR was described as being a
tool for advancing evidence-based practice while im-
proving health care quality and safety. The increasing
budgetary pressure facing governments and health care
systems was also described as a key factor prompting the
development of HTR programs.
Throughout the interviews, it became clear that there
are many methods for completing reassessments, with
little standardization internationally. Some interviewees
explained that they did not have a separate HTR pro-
gram, but rather had integrated HTR into their HTA
work. One person working in a unit at the health service
delivery level stated that: “. . .lots of people do little pro-
jects that essentially have an element of disinvestment in
them, but nobody is using that terminology.” Organiza-
tions also conducted reassessments in varying degrees
of depth. Some described taking a broader look at
evidence-based practices (using both HTA and HTR),
for example, reassessing all of the technologies from
an entire clinical issue or area, whereas other organiza-
tions described reassessing one particular procedure or
technology at a time.
The interview participants all encountered significant
barriers while implementing their HTR programs.
Some of the key barriers frequently cited included a
poor evidence base, political push-back, a large invest-
ment of work and time for relatively small cost-savings,
influence of industry, and difficulty communicating witha variety of audiences. Many methods for mitigating
these barriers were proposed with the top two being
stakeholder engagement and champion involvement.
Having a champion involved who can provide top-
down support emerged from the interviews as a key
strategy for developing and implementing a successful
HTR program. This finding echoes the survey results
presented earlier. During the interviews, one resarcher
noted that HTR: ". . .is potentially controversial and
often, ideologically not well aligned with political inter-
ests, so having a political champion who is receptive. . .is
important.”
Interview participants described stakeholder engage-
ment as necessary for success, noting that it was crucial
to engage stakeholders promptly and continuously to be
successful with HTR. As one senior government official
commented: “We take them on the journey with us.” To
this end, interview participants spoke at length about
ways of engaging stakeholders; including the importance
of presenting the reassessment findings in a way that is
comprehensible and intuitive to a diverse health profes-
sional and public audience. Many approaches were high-
lighted in these conversations. Integrating reassessment
findings, along with other kinds of evidence-based gui-
dance, into care pathways was often brought up as a
successful strategy, as this quote illustrates: “The clini-
cians and even patients. . .found that the most interactive
and the most easily understood [approach to presenting
the guidance] was the pathway of care they needed to
follow. . . Looking at all the appraisals and guideli-
nes. . .they all need to feed into the same clinical area. . .
[we have determined] that would be the way to best
present our information.”
Participants were also asked to describe the model, or
framework, they used to complete their reassessments.
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developed by those delivering the HTR programs. It
was regularly stressed that models were highly
context-dependent (i.e., people develop models that
will work in their unique context), meaning models
developed elsewhere were difficult to adopt without
modifications. None of the interviewees indicated that
they had used a model developed elsewhere. Inter-
view participants also emphasized that models and
HTR processes tend to evolve over time based on
successes and failures; so having a flexible model was
imperative.
Although models and corresponding processes were
developed to fit local context, many models do incor-
porate many of the same broad stages or steps. Most
begin with a new or existing committee identifying
and prioritizing potentially obsolete technologies for
reassessment, while beginning to engage potential sta-
keholders and clinical experts. Prioritization is often
based on some combination of utilization rates, ease
of reassessment, mechanisms for change and potential
cost savings. A review is then conducted on the
selected technology and a recommendation or decision
is put forth based on the collected evidence and input
from stakeholders. The results of a reassessment are
often made available through public websites, news
releases and\or academic publications.
Since most final funding decisions are made at the
governmental level, successful HTR implementation re-
lies on processes outside the control of the orga-
nization conducting the review. One interviewee noted
that approximately 50% of the time, the decision-
making body accepted the recommendations coming
from the review and advised the government to imple-
ment the decision. In this case, the government almost
always acted on the Board’s advice. This rate of con-
cordance reflects the political and social influences on
decision-making.
Interview data suggests that reinvestment strategies
are either lacking or unknown. This may be because
monitoring processes are not in place and/or because
reallocation decisions are beyond the scope of the
organization’s mandate. Whether money saved can be
reallocated back to the same clinical area toward a
more effective technology is dependent on the type of
savings and how budgets are allocated. In health care
delivery organizations, for example, sometimes the sa-
vings occur in areas that are not aligned with a particular
clinical department (e.g., decreased length-of-stay). One
interview participant noted that it would be difficult to
keep track of cost-savings: ". . .trying to measure that
without a health economist expertise is going to be really
difficult. I think we may not be able to quantify the
savings.”Discussion
Results of this research indicate that many organizations
realize the potential benefits of HTR and are interested
in integrating it into their health care system. However,
a lack of top-down support, push back from clinicians,
financial and human resource limitations, and a lack of
expertise in health re-assessment are inhibiting program
development.
Those with developed programs offered sage advice
for successful program development and implementa-
tion. It was often reiterated by interview participants
that when launching a program, it is ideal to select tech-
nologies where the reassessment process is unlikely to
be lengthy and will result in significant fund liberation.
This will increase the likelihood that public understand-
ing of HTR will be improved and get relevant stake-
holders on board.
The importance of learning from successes and fail-
ures, and having the flexibility to adjust models and pro-
cesses accordingly was frequently highlighted. Similarly,
it was continually reiterated that communication with
stakeholders is critical to the success of a HTR program.
Stakeholders must be engaged early, continuously and as
extensively as resources allow. With implementation, it
is important to have people and processes in place to
move a decision into practice and policy.
There is no commonly accepted model for reassessing
health technologies and very little agreement on specific
methods amongst those completing HTRs. Although
interview participants revealed that models must be very
context-dependent, having even a broad outline of steps
and stages based on effective HTR programs may help
develop more successful programs.
Such a model must include reinvestment and monitor-
ing; two elements infrequently incorporated into current
models. In the development of these stages, international
collaboration and perspectives would increase the ap-
plicability of such a model. There are a few experts who
possess a wealth of experience-based knowledge on the
subject. Since there are few people who have in depth
knowledge of this field, many people indicated that not
having expert knowledge within their organization was
preventing them from developing a HTR program. For
this field to develop to its full potential, an emphasis on
communication and collaboration between interested
organizations is essential. Focusing on using collabo-
ration and knowledge-sharing as a means to move the
HTR agenda forward has been emphasized in current
literature [6-8].
This study has limitations. The survey response rate
was low; as this is a new and small field, this was antici-
pated. The sampling frame was intentionally broad and
over-inclusive to ensure that all potential respondents
were captured. The number of key-informants was
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across the interviews, indicating that we were close to
achieving saturation in the thematic areas reported here.
Conclusions
HTR has the potential to improve the quality of care
patients receive, promote evidence-based practice and
improve health care sustainability. It is a powerful tool
that is not being used to its full potential internationally.
However, it is currently limited by an under-developed
theoretical base, a small field of experts and limited
reporting of case studies in the literature. Future work
should focus on advancing the theoretical framework for
HTR drawing upon developed theories in knowledge
translation and implementation science. In addition, case
reports of HTR applications that include a strong moni-
toring and evaluation component should be reported in
the scientific literature. This will contribute to the deve-
lopment of a body of knowledge from practice that has
great potential to improve our understanding of what
works and what does not work in which contexts and
why, that those embarking upon HTR could draw upon.
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